Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2005

View Archived Issues

Cenix and Instituto de Medicina Molecular work together in malaria

Pivotal phase III study begins for Technosphere Insulin

Enrollment nears completion in ARISE study of AGI-1067

Sumitomo licenses amrubicin hydrochloride to Conforma Therapeutics

First phase III study begins for Evizon in wet AMD

Peplin progresses PEP-005 Topical for actinic keratosis

Altana and Pfizer terminate Daxas collaboration

Paradigm signs agreement with Ortho-McNeil in pain and urinary incontinence

Agensys submits IND for phase I study of AGS-PSCA

Johnson & Johnson completes acquisition of Peninsula Pharmaceuticals

New approval for Topamax

Genzyme acquisition of Bone Care International approved by shareholders

Novel analgesics reported in patent literature

Procyon reflects on FY2004

Recent patents cover novel antiinfective agents

Valera seeks Danish approval for Vantas

SR Pharma to acquire Atugen

Factor Xa inhibitors, PAI-1 inhibitors in early development

ZK-187638 is neuroprotective after permanent focal cerebral ischemia in mice

SUN-N5147 mediates potent antiischemic effects in rats

Sant-7 potentiates the effect of dexamethasone against multiple myeloma

Fujisawa scientists discover selective and orally active IP receptor agonist

Kos inhaled insulin shows promise as adjunct therapy for type 2 diabetes

Preclinical evidence confirms the antidiabetic effects of CKD-501

SSR-180575 demonstrates antiischemic effects in cardiac ischemia model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...